available for iOS, Android & web
July 22, 2015
May 11, 2015
February 20, 2015
September 02, 2014
Certain patients with diabetic macular oedema can be treated with the implant
July 27, 2014
Five new drugs put forward for European approval
June 30, 2014
Second CRL for the migraine aerosol therapy
June 07, 2011
Novartis has received clearance in Europe to market its eye drug Lucentis for macular oedema secondary to retinal vein occlusion, a disease than can cause severe damage to the retina, visual impairment and ultimately blindness.
Allergan will no doubt be breathing a sigh of relief after cost regulators published final draft guidance endorsing its eye implant Ozurdex for use in National Health Service patients with macular oedema.
February 08, 2011
Cost regulators for the National Health Service in England and Wales have asked Allergan to provide more data on its macular oedema eye implant Ozurdex, particulary on how it compares to Roche/Genentech's Avastin.
Limited Marketer of the Year tickets available!
Read more here
PharmaTimes 2015 Copyright | RSS Feed Subscriptions